Dr. Laura Mauri will drive integration of medical and scientific intelligence and patient safety and engagement as chief scientific, medical and regulatory officer

DUBLIN, April 25, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT) today announced that Laura Mauri, M.D., M.S.c. has been appointed Medtronic Chief Scientific, Medical and Regulatory Officer. This appointment adds to Dr. Mauri's prior responsibilities as chief clinical and regulatory officer, aligning and integrating the company's scientific, medical, clinical research and regulatory affairs under her leadership. It leverages her deep expertise and understanding of the interaction between patients and medical technology to accelerate innovation that puts patients first. Dr. Mauri will also continue to serve as a member of the Medtronic Executive Committee.

"With this appointment, we're enabling a patient-centered approach to healthcare technology innovation at every stage of the product lifecycle," said Geoff Martha, chairman and CEO, Medtronic. "Dr. Mauri's expertise and leadership connects medical and scientific intelligence, ensuring we have a clear appraisal of the medical and scientific landscape as we make investment decisions, and helping to deliver effective and reliable innovations for patients and healthcare providers."

Priorities for Dr. Mauri include delivering a transformative approach to both patient safety and patient engagement. She recently hired Olaf Hedrich, M.D., a patient safety, risk and analytics industry expert to serve as the company's Chief Medical Safety Officer, responsible for leading an independent medical safety organization that will provide expert input to assure patients safety and quality across Medtronic products. She will also lead the integration of robust and independent medical expertise into the company's business processes, including investment decisions, business development, exploration of therapeutic areas and development of novel technologies.

"Medtronic is fortunate to have world-leading experts across diverse scientific and medical fields who provide unique insights and breakthrough discoveries. I'm excited to integrate this expertise across our company, to connect technology innovation with better health outcomes for patients," said Dr. Mauri. "A strong scientific and patient-centered mindset across all stages of device development will enable innovation that saves and improves lives."

Dr. Mauri joined Medtronic in September 2018 and became a member of the company's Executive Committee in August 2020. In her time with the company, she has provided innovative leadership to trial design and data science, created new evidence pathways, provided medical and scientific input to investment decisions, delivered leadership to patient safety, and sponsored regulatory advances that have positively impacted patients worldwide. 

Prior to joining Medtronic, Dr. Mauri was a practicing interventional cardiologist at the Brigham and Women's Hospital for 15 years and an internationally renowned investigator and professor of medicine at Harvard Medical School.

Dr. Mauri succeeds Richard Kuntz, M.D., M.S.c. as Chief Medical and Scientific Officer, who previously announced his retirement, effective April 29.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 90,000+ passionate people across 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE:MDT), visit www.Medtronic.com and follow @Medtronic on Twitter and LinkedIn.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

SOURCE Medtronic plc